logo
Could this shot end Lyme disease forever?

Could this shot end Lyme disease forever?

Fast Company6 hours ago
The list of summertime scourges grows longer each year: wildfires, heat waves, floods. And we can now add to that a veritable infestation of biting, Lyme-disease-carrying ticks. Emergency room visits for tick bites in the Northeast are at their highest levels in at least five years. This June, the Centers for Disease Control and Prevention recorded 229 tick bites per every 100,000 visits to ERs around the Northeast, up from 167 bites per 100,000 visits a year earlier.
Nationwide, more than 89,000 cases of Lyme disease were reported to the CDC in 2023 through state health departments. But a CDC analysis of insurance claims suggests that actual cases of people seeking treatment for Lyme disease—transmitted by black-legged ticks infected with Borrelia burgdorferi bacteria—could be about 476,000 annually.
While most cases still occur in the Northeast, mid-Atlantic, and upper Midwest regions, climate change is expanding the ticks' habitat, and the transmission season is getting longer, starting earlier each spring and stretching well into late fall. (Ticks can be active any time the temperature is above freezing.)
If you spot the symptoms—a target-like rash, fever, headache, extreme fatigue—early enough, treating Lyme disease with antibiotics has a high success rate. But Lyme disease is often undetected and untreated, and that can lead to long-term, chronic problems with the joints, heart, and nervous system.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Yahoo

time17 minutes ago

  • Yahoo

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Partnership includes joint collaboration initiatives to improve precision medicine and accelerate innovation in cancer pathology BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation's top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI's digital pathology platform, AISight® Dx, across Moffitt's pathology programs to transform cancer detection and innovation. AISight® Dx, is PathAI's cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine. 'We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,' said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. 'By deploying AISight® Dx and building this strategic partnership, we're equipping Moffitt's pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.' 'This collaboration aligns perfectly with Moffitt's mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,' said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. 'By deploying AISight® Dx into our pathology infrastructure, we're taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review. 'Adopting cutting-edge digital pathology technologies is key to driving Moffitt's vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,' said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. 'By partnering with PathAI, we're laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI's and Moffitt's legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.' Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology. For more information about PathAI, or AISight Dx, please contact or visit 1AISight® is for Research Use Only in the US; AISight® Dx is FDA-cleared for primary diagnosis in the US, and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, visit About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit and follow the momentum on Facebook, X, Instagram and YouTube. Company Contact Liz Storti Chief People Officer Media Contact Owen Blaschak LifeSci Communications oblaschak@

Federal investigators demanded details on transgender patients from at least 1 hospital
Federal investigators demanded details on transgender patients from at least 1 hospital

Yahoo

time17 minutes ago

  • Yahoo

Federal investigators demanded details on transgender patients from at least 1 hospital

When the U.S. Justice Department sought information from doctors and clinics that provide gender-affirming care for young transgender patients, officials weren't just asking for policies. They also demanded information about individual patients. Attorney General Pam Bondi announced in a statement July 9 that the department had sent more than 20 subpoenas to doctors and clinics that provide the care. The request represented an elevation in President Donald Trump's administration's effort to halt the medical treatment for transgender youth, even in states where it's legal. Bondi said the requests were part of investigations into 'healthcare fraud, false statements, and more.' No charges have been announced so far, but the probes have had a chilling impact on the availability of care. Specifics of the requests were not made public until a court filing in a separate lawsuit this week. Advocates say the requests are invasive and unnecessary. 'It turns doctor-patient confidentiality into government surveillance,' said Jennifer Levi, GLAD Law's senior director of Transgender and Queer Rights. At least one of the requests seeks names and social security numbers of patients The subpoena sent to Children's Hospital of Philadelphia on June 11 was included in a legal filing Monday in challenges from the states of Minnesota, Oregon and Washington to the administration's attempts to bar the treatment for patients under age 19. The 18-page document demanded an expansive list of documents be provided. Among them: Documents to identify 'by name, date of birth, social security number, address and parent/guardian information' patients who were prescribed puberty blockers or hormone therapy. The requests also covered personnel files for various categories of hospital employees, information about patient intake procedures and about which insurance billing codes the hospital used for gender-affirming care. The due date listed was July 9. It's not clear whether subpoenas sent to other providers were identical. Neither the hospital nor the Department of Justices responded to requests for comment on Thursday. Gender-affirming care has emerged as part of a political and legal battle Gender-affirming care includes a range of medical and mental health services to support a person's gender identity, including when it's different from the sex they were assigned at birth. It encompasses counseling, medications that block puberty and hormone therapy to produce physical changes as well as surgeries to transform chests and genitals, though those are rare for minors. Most major medical groups say access to the treatment is important for those with gender dysphoria and see gender as existing along a spectrum. While there's wide, if not universal, medical consensus, the political situation is contentious. Since 2021, at least 27 states have adopted laws restricting or banning the care for minors, and a U.S. Supreme Court ruling in June affirmed the states' right to have such policies, at least under certain conditions. Trump has signed one executive order defining sex as only male or female — and as unchangeable — and another that seeks to end federal funding of the care for patients under 19. He's also sought to bar transgender military service members and keep transgender athletes out of certain sports competitions. And the administration released a document that questions the standards of treatment for transgender youth and suggests relying solely on talk therapy rather than medical interventions. The investigation is one reason some clinics have halted the care At least eight major hospitals and hospital systems announced in July that they were stopping or restricting gender-affirming care, even though they're in states where it is not banned. Children's Hospital of Philadelphia is not among those that have announced they're curtailing care, though a place it has referred patients for surgeries — Penn Medicine — said in May that it would no longer perform them on patients under 19. A group of Democratic state officials across the country are suing the Trump administration, claiming it is intimidating healthcare providers to stop the care. GLAD Law's Levi said the investigation is just one of many factors that have led providers to change their policies. 'It's chilling,' she said. Solve the daily Crossword

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Associated Press

time20 minutes ago

  • Associated Press

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation's top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI's digital pathology platform, AISight® Dx, across Moffitt's pathology programs to transform cancer detection and innovation. AISight® Dx, is PathAI's cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine. 'We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,' said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. 'By deploying AISight ® Dx and building this strategic partnership, we're equipping Moffitt's pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.' 'This collaboration aligns perfectly with Moffitt's mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,' said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. 'By deploying AISight® Dx into our pathology infrastructure, we're taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review. 'Adopting cutting-edge digital pathology technologies is key to driving Moffitt's vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,' said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. 'By partnering with PathAI, we're laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI's and Moffitt's legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.' Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology. For more information about PathAI, or AISight Dx, please contact [email protected] or visit 1 AISight® is for Research Use Only in the US; AISight® Dx is FDA-cleared for primary diagnosis in the US, and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, visit About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit and follow the momentum on Facebook, X, Instagram and YouTube. Company Contact Liz Storti Chief People Officer [email protected] Media Contact Owen Blaschak LifeSci Communications [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store